Nutrition Policy and Scientific Advice Unit, Department of Nutrition for Health and Development, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
BMJ. 2013 Apr 3;346:f1378. doi: 10.1136/bmj.f1378.
To conduct a systematic review of the literature and meta-analyses to fill the gaps in knowledge on potassium intake and health.
Cochrane Central Register of Controlled Trials, Medline, Embase, WHO International Clinical Trials Registry Platform, Latin American and Caribbean Health Science Literature Database, and the reference lists of previous reviews.
Randomised controlled trials and cohort studies reporting the effects of potassium intake on blood pressure, renal function, blood lipids, catecholamine concentrations, all cause mortality, cardiovascular disease, stroke, and coronary heart disease were included.
Potential studies were independently screened in duplicate, and their characteristics and outcomes were extracted. When possible, meta-analysis was done to estimate the effects (mean difference or risk ratio with 95% confidence interval) of higher potassium intake by using the inverse variance method and a random effect model.
22 randomised controlled trials (including 1606 participants) reporting blood pressure, blood lipids, catecholamine concentrations, and renal function and 11 cohort studies (127,038 participants) reporting all cause mortality, cardiovascular disease, stroke, or coronary heart disease in adults were included in the meta-analyses. Increased potassium intake reduced systolic blood pressure by 3.49 (95% confidence interval 1.82 to 5.15) mm Hg and diastolic blood pressure by 1.96 (0.86 to 3.06) mm Hg in adults, an effect seen in people with hypertension but not in those without hypertension. Systolic blood pressure was reduced by 7.16 (1.91 to 12.41) mm Hg when the higher potassium intake was 90-120 mmol/day, without any dose response. Increased potassium intake had no significant adverse effect on renal function, blood lipids, or catecholamine concentrations in adults. An inverse statistically significant association was seen between potassium intake and risk of incident stroke (risk ratio 0.76, 0.66 to 0.89). Associations between potassium intake and incident cardiovascular disease (risk ratio 0.88, 0.70 to 1.11) or coronary heart disease (0.96, 0.78 to 1.19) were not statistically significant. In children, three controlled trials and one cohort study suggested that increased potassium intake reduced systolic blood pressure by a non-significant 0.28 (-0.49 to 1.05) mm Hg.
High quality evidence shows that increased potassium intake reduces blood pressure in people with hypertension and has no adverse effect on blood lipid concentrations, catecholamine concentrations, or renal function in adults. Higher potassium intake was associated with a 24% lower risk of stroke (moderate quality evidence). These results suggest that increased potassium intake is potentially beneficial to most people without impaired renal handling of potassium for the prevention and control of elevated blood pressure and stroke.
系统综述文献和荟萃分析,以填补钾摄入与健康相关知识的空白。
Cochrane 对照试验中心注册库、医学文献在线数据库、Embase、世界卫生组织国际临床试验注册平台、拉丁美洲和加勒比健康科学文献数据库以及先前综述的参考文献列表。
纳入报告钾摄入对血压、肾功能、血脂、儿茶酚胺浓度、全因死亡率、心血管疾病、卒中和冠心病影响的随机对照试验和队列研究。
独立进行了潜在研究的双重筛选,并提取了其特征和结果。当可能时,使用逆方差法和随机效应模型进行荟萃分析,以估计更高钾摄入的效果(均值差或风险比及其 95%置信区间)。
纳入了 22 项随机对照试验(包括 1606 名参与者),报告了血压、血脂、儿茶酚胺浓度和肾功能,以及 11 项队列研究(包括 127038 名参与者),报告了全因死亡率、心血管疾病、卒中和冠心病在成年人中。荟萃分析显示,钾摄入增加可使成年人的收缩压降低 3.49(95%置信区间 1.82 至 5.15)mmHg,舒张压降低 1.96(0.86 至 3.06)mmHg,这一效果仅见于高血压患者,而在非高血压患者中则未见。当更高的钾摄入量为 90-120mmol/天时,收缩压降低了 7.16(1.91 至 12.41)mmHg,没有剂量反应。在成年人中,钾摄入增加对肾功能、血脂或儿茶酚胺浓度没有显著的不良影响。钾摄入与卒中风险呈负相关(风险比 0.76,0.66 至 0.89)。钾摄入与心血管疾病(风险比 0.88,0.70 至 1.11)或冠心病(0.96,0.78 至 1.19)风险之间的关联无统计学意义。在儿童中,三项对照试验和一项队列研究表明,钾摄入增加使收缩压降低了非显著的 0.28(-0.49 至 1.05)mmHg。
高质量证据表明,钾摄入增加可降低高血压患者的血压,且对成年人的血脂浓度、儿茶酚胺浓度或肾功能无不良影响。更高的钾摄入量与卒中风险降低 24%相关(中等质量证据)。这些结果表明,增加钾摄入可能对大多数肾功能未受损的人有益,可预防和控制血压升高和卒中。